Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement

Pharmacology and Therapeutics

Volumn 165, Issue , 2016, Pages 79-92

  Morgan, Molly M ^a   Johnson, Brian P ^a   Livingston, Megan K ^a   Schuler, Linda A ^b   Alarid, Elaine T ^a   Sung, Kyung E ^a   Beebe, David J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Adverse outcome pathway; Chemotherapy sensitivity and resistance assays; Microenvironment; Personalized medicine; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ASSAY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CONCEPTUAL FRAMEWORK; ECOLOGY; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TOXICOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; CELL SEPARATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PRIMARY CELL CULTURE; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL SEPARATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; PATIENT SELECTION; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84970021146     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.05.007     Document Type: Review

References (224)

1. Aboussekhra, A., Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int J Dev Biol 55:7–9 (2011), 841–849.
2. Albini, A., Graf, J., Kitten, G.T., Kleinman, H.K., Martin, G.R., Veillette, A., et al. 17 beta-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci U S A 83:21 (1986), 8182–8186.
3. Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6 (2004), 17–32 (United States).
4. Ankley, G.T., Bennett, R.S., Erickson, R.J., Hoff, D.J., Hornung, M.W., Johnson, R.D., et al. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29:3 (2010), 730–741.
5. Applanat, M.P., Buteau-Lozano, H., Herve, M.A., Corpet, A., Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol 617 (2008), 437–444.
6. Bailey, S.T., Shin, H., Westerling, T., Liu, X.S., Brown, M., Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A 109:44 (2012), 18060–18065.
7. Bartlett, R., Everett, W., Lim, S., G N, Loizidou, M., Jell, G., et al. Personalized in vitro cancer modeling — fantasy or reality?. Transl Oncol 7 (2014), 657–664.
8. Bertelsen, C.A., Sondak, V.K., Mann, B.D., Korn, E.L., Kern, D.H., Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer 53:6 (1984), 1240–1245.
9. Beverage, J.N., Sissung, T.M., Sion, A.M., Danesi, R., Figg, W.D., CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 96:9 (2007), 2224–2231.
10. Bevilacqua, G., Bosman, F., Dassesse, T., Hofler, H., Janin, A., Langer, R., et al. The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch 456:4 (2010), 449–454.
11. Bhagwandin, S., Naffouje, S., Salti, G., Utility of chemoresponse assay in patients undergoing cytoreductive surgery plus hyperthermic Intraperitoneal chemotherapy. Ann Surg Oncol 22:8 (2015), 2573–2577.
12. Birgersdotter, A., Sandberg, R., Ernberg, I., Gene expression perturbation in vitro—a growing case for three-dimensional (3D) culture systems. Semin Cancer Biol 15:5 (2005), 405–412.
13. Bischel, L.L., Beebe, D.J., Sung, K.E., Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure. BMC Cancer, 15, 2015, 12.
14. Bischel, L.L., Young, E.W., Mader, B.R., Beebe, D.J., Tubeless microfluidic angiogenesis assay with three-dimensional endothelial-lined microvessels. Biomaterials 34:5 (2013), 1471–1477.
15. Bjornstrom, L., Sjoberg, M., Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:4 (2005), 833–842.
16. Blackwell, K.L., Haroon, Z.A., Shan, S., Saito, W., Broadwater, G., Greenberg, C.S., et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6:11 (2000), 4359–4364.
17. Blevins-Primeau, A.S., Sun., D., Chen, G., Sharma, A.K., Gallagher, C.J., Amin, S., et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 69:5 (2009), 1892–1900.
18. Bohrer, L.R., Schwertfeger, K.L., Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a Cxcr2-dependent manner. Mol Cancer Res 10:10 (2012), 1294–1305.
19. Bosch, T.M., Meijerman, I., Beijnen, J.H., Schellens, J.H., Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:3 (2006), 253–285.
20. Bourdeau, V., Deschenes, J., Metivier, R., Nagai, Y., Nguyen, D., Bretschneider, N., et al. Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18:6 (2004), 1411–1427.
21. Bracke, M.E., Charlier, C., Bruyneel, E.A., Labit, C., Mareel, M.M., Castronovo, V., Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 54:17 (1994), 4607–4609.
22. Bulun, S.E., Lin, Z., Zhao, H., Lu, M., Amin, S., Reierstad, S., et al. Regulation of aromatase expression in breast cancer tissue. Ann N Y Acad Sci 1155 (2009), 121–131.
23. Burrell, R.A., McGranahan, N., Bartek, J., Swanton, C., The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501 (2013), 338–345.
24. Burstein, H.J., Mangu, P.B., Somerfield, M.R., Schrag, D., Samson, D., Holt, L., et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29:24 (2011), 3328–3330.
25. Butterick, T.A., Duffy, C.M., Lee, R.E., Billington, C.J., Kotz, C.M., Nixon, J.P., Use of a caspase multiplexing assay to determine apoptosis in a hypothalamic cell model. J Vis Exp, 86, 2014.
26. Caldon, C.E., Estrogen signaling and the DNA damage response in hormone dependent breast cancers. Front Oncol, 4, 2014.
27. Calippe, B., Douin-Echinard, V., Delpy, L., Laffargue, M., Lelu, K., Krust, A., et al. 17Beta-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo. J Immunol 185:2 (2010), 1169–1176.
28. Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47 (2015), 320–329.
29. Campbell, L., Emmerson, E., Williams, H., Saville, C.R., Krust, A., Chambon, P., et al. Estrogen receptor-alpha promotes alternative macrophage activation during cutaneous repair. J Invest Dermatol 134:9 (2014), 2447–2457.
30. Cavalieri, E., Frenkel, K., Liehr, J.G., Rogan, E., Roy, D., Estrogens as endogenous genotoxic agents–DNA adducts and mutations. J Natl Cancer Inst Monogr(27), 2000, 75–93.
31. Chang, J.C., Wooten, E.C., Tsimelzon, A., Hilsenbeck, S.G., Gutierrez, M.C., Elledge, R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:9381 (2003), 362–369.
32. Chen, L., Xiao, Z., Meng, Y., Zhao, Y., Han, J., Su, G., et al. The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials 33:5 (2012), 1437–1444.
33. Chin, L., Andersen, J.N., Futreal, P.A., Cancer genomics: from discovery science to personalized medicine. Nat Med 17 (2011), 297–303.
34. Chitcholtan, K., Asselin, E., Parent, S., Sykes, P.H., Evans, J.J., Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. Exp Cell Res 319:1 (2013), 75–87.
35. Ciocca, D.R., Fanelli, M.A., Estrogen receptors and cell proliferation in breast cancer. Trends Endocrinol Metab 8:8 (1997), 313–321.
36. Cree, I.A., Andreotti, P.E., Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines. Toxicol In Vitro 11:5 (1997), 553–556.
37. Cree, I.A., Glaysher, S., Harvey, A.L., Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10:4 (2010), 375–379.
38. Cree, I.A., Kurbacher, C.M., Lamont, A., Hindley, A.C., Love, S., A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18:9 (2007), 1093–1101.
39. Cronin-Fenton, D.P., Damkier, P., Lash, T.L., Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol 10:1 (2014), 107–122.
40. Dabrosin, C., Margetts, P.J., Gauldie, J., Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J Cancer 107:4 (2003), 535–540.
41. Dabrosin, C., Palmer, K., Muller, W.J., Gauldie, J., Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res Treat 78:1 (2003), 1–6.
42. Dairkee, S.H., Ji, Y., Ben, Y., Moore, D.H., Meng, Z., Jeffrey, S.S., A molecular ‘signature’ of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics, 5(1), 2004, 47.
43. Davies, M.A., Samuels, Y., Analysis of the genome to personalize therapy for melanoma. Oncogene 29:41 (2010), 5545–5555.
44. Demirpence, E., Duchesne, M.J., Badia, E., Gagne, D., Pons, M., MVLN cells: a bioluminescent MCE-7-derived cell line to study the modulation of estrogenic activity. J Steroid Biochem Mol Biol 46:3 (1993), 355–364.
45. Desoize, B., Gimonet, D., Jardiller, J.C., Cell culture as spheroids: an approach to multicellular resistance. Anticancer Res 18:6a (1998), 4147–4158.
46. Desta, Z., Ward, B.A., Soukhova, N.V., Flockhart, D.A., Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:3 (2004), 1062–1075.
47. Dias-Santagata, D., Akhavanfard, S., David, S.S., Vernovsky, K., Kuhlmann, G., Boisvert, S.L., et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:5 (2010), 146–158.
48. Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 71:7 (2011), 2455–2465.
49. Doisneau-Sixou, S.F., Sergio, C.M., Carroll, J.S., Hui, R., Musgrove, E.A., Sutherland, R.L., Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10:2 (2003), 179–186.
50. Edwards, S.W., Tan, Y.M., Villeneuve, D.L., Meek, M.E., McQueen, C.A., Adverse outcome pathways—organizing toxicological information to improve decision making. J Pharmacol Exp Ther 356:1 (2016), 170–181.
51. Ellis, P.A., Saccani-Jotti, G., Clarke, R., Johnston, S.R., Anderson, E., Howell, A., et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 72:4 (1997), 608–613.
52. Estes, D.A., Lovato, D.M., Khawaja, H.M., Winter, S.S., Larson, R.S., Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol 139:1 (2007), 20–30.
53. Felty, Q., Roy, D., Estrogen, mitochondria, and growth of cancer and non-cancer cells. (in review) J Carcinog, 4(1), 2005, 1.
54. Felty, Q., Singh, K.P., Roy, D., Estrogen-induced G1 |[sol]|S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 24:31 (2005), 4883–4893.
55. Ferrara, N., Hillan, K.J., Gerber, H.-P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:5 (2004), 391–400.
56. Ferriss, J.S., Rice, L.W., The role of in vitro directed chemotherapy in epithelial ovarian cancer. Rev Obstet Gynecol 3:2 (2010), 49–54.
57. Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:18 (1998), 1371–1388.
58. Fruehauf, J.P., In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 9:3 (2002), 171–182.
59. Fruehauf, J.P., Alberts, D.S., In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 23 (2005), 3641–3643 (author reply 3646–3648). United States).
60. Gajewski, T.F., Schreiber, H., Fu, Y.-X., Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14 (2013), 1014–1022.
61. Gallion, H., Christopherson, W.A., Coleman, R.L., DeMars, L., Herzog, T., Hosford, S., et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16:1 (2006), 194–201.
62. Gao, D., Vela, I., Sboner, A., Iaquinta, P.J., Karthaus, W.R., Gopalan, A., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159:1 (2014), 176–187.
63. Gerets, H.H., Hanon, E., Cornet, M., Dhalluin, S., Depelchin, O., Canning, M., et al. Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicol In Vitro 23:2 (2009), 319–332.
64. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:10 (2012), 883–892.
65. Ginsburg, G.S., McCarthy, J.J., Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 19:12 (2001), 491–496.
66. Gjerde, J., Hauglid, M., Breilid, H., Lundgren, S., Varhaug, J.E., Kisanga, E.R., et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:1 (2008), 56–61.
67. Gottesman, M.M., Mechanisms of cancer drug resistance. Annu Rev Med 53 (2002), 615–627.
68. Gravendeel, L.A., Kouwenhoven, M.C., Gevaert, O., de Rooi, J.J., Stubbs, A.P., Duijm, J.E., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69:23 (2009), 9065–9072.
69. Group, E.B.C.T.C., Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:9114 (1998), 1451–1467.
70. Hall, J.M., Couse, J.F., Korach, K.S., The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276:40 (2001), 36869–36872.
71. Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:33 (2007), 5287–5312.
72. Haslam, S.Z., Woodward, T.L., Host microenvironment in breast cancer development: epithelial-cell–stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. (in review) Breast Cancer Res, 5(4), 2003, 208.
73. Hayashi, S.I., Eguchi, H., Tanimoto, K., Yoshida, T., Omoto, Y., Inoue, A., et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10:2 (2003), 193–202.
74. Hayes, E.L., Lewis-Wambi, J.S., Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. (in review) Breast Cancer Res, 17(1), 2015, 40.
75. Hayward, S.W., Dahiya, R., Cunha, G.R., Bartek, J., Deshpande, N., Narayan, P., Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31:1 (1995), 14–24.
76. Herzog, T.J., Krivak, T.C., Fader, A.N., Coleman, R.L., Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol, 203(1), 2010, 68 (e61–66).
77. Hidalgo, M., Bruckheimer, E., Rajeshkumar, N., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10:8 (2011), 1311–1316.
78. Higashiyama, M., Oda, K., Okami, J., Maeda, J., Kodama, K., Imamura, F., et al. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer 68:3 (2010), 472–477.
79. Hirsch, F.R., Spreafico, A., Novello, S., Wood, M.D., Simms, L., Papotti, M., The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 3:12 (2008), 1468–1481.
80. Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., Kunz-Schughart, L.A., Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148:1 (2010), 3–15.
81. Hoelder, S., Clarke, P.A., Workman, P., Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 6:2 (2012), 155–176.
82. Hooper, K., Multiplexing cell-based assays: get more biologically relevant data., 2011 Retrieved from http://www.promega.com/~/pdf/resources/pubhub/multiplexing-cell-based-assays-get-more-biologically-relevant-data/.
83. Hsiao, A.Y., Torisawa, Y.S., Tung, Y.C., Sud, S., Taichman, R.S., Pienta, K.J., et al. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials 30:16 (2009), 3020–3027.
84. Hsieh, C.H., Chen, Y.D., Huang, S.F., Wang, H.M., Wu, M.H., The effect of primary cancer cell culture models on the results of drug chemosensitivity assays: the application of perfusion microbioreactor system as cell culture vessel. Biomed Res Int, 2015.
85. Huang, L., Holtzinger, A., Jagan, I., BeGora, M., Lohse, I., Ngai, N., et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med 21:11 (2015), 1364–1371.
86. Improta-Brears, T., Whorton, A.R., Codazzi, F., York, J.D., Meyer, T., McDonnell, D.P., Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A 96:8 (1999), 4686–4691.
87. Ioachim, E., Charchanti, A., Briasoulis, E., Karavasilis, V., Tsanou, H., Arvanitis, D.L., et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38:18 (2002), 2362–2370.
88. Iusuf, D., Teunissen, S.F., Wagenaar, E., Rosing, H., Beijnen, J.H., Schinkel, A.H., P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther 337:3 (2011), 710–717.
89. Ivshina, A.V., George, J., Senko, O., Mow, B., Putti, T.C., Smeds, J., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:21 (2006), 10292–10301.
90. Iyer, L., Das, S., Janisch, L., Wen, M., Ramirez, J., Karrison, T., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:1 (2002), 43–47.
91. Jeon, J.S., Bersini, S., Gilardi, M., Dubini, G., Charest, J.L., Moretti, M., et al. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci U S A 112:1 (2015), 214–219.
92. Jimenez-Torres, J.A., Peery, S.L., Sung, K.E., Beebe, D.J., LumeNEXT: a practical method to pattern luminal structures in ECM gels. Adv Healthc Mater, 2015.
93. Johansson, I., Ingelman-Sundberg, M., Genetic polymorphism and toxicology—with emphasis on cytochrome p450. Toxicol Sci 120:1 (2011), 1–13.
94. Joo, W.D., Lee, J.Y., Kim, J.H., Yoo, H.J., Roh, H.J., Park, J.Y., et al. Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J Gynecol Oncol 20:2 (2009), 96–100.
95. Justice, B.A., Badr, N.A., Felder, R.A., 3D cell culture opens new dimensions in cell-based assays. Drug Discov Today 14:1–2 (2009), 102–107.
96. Kenny, P.A., Lee, G.Y., Myers, C.A., Neve, R.M., Semeiks, J.R., Spellman, P.T., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:1 (2007), 84–96.
97. Khademhosseini, A., Langer, R., Borenstein, J., Vacanti, J.P., Microscale technologies for tissue engineering and biology. Proc Natl Acad Sci U S A 103:8 (2006), 2480–2487.
98. Kim, J.B., Stein, R., O'Hare, M.J., Three-dimensional in vitro tissue culture models of breast cancer— a review. Breast Cancer Res Treat 85:3 (2004), 281–291.
99. Kim, K.U., Wilson, S.M., Abayasiriwardana, K.S., Collins, R., Fjellbirkeland, L., Xu, Z., et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33:6 (2005), 541–548.
100. Kiyotani, K., Mushiroda, T., Nakamura, Y., Zembutsu, H., Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet 27:1 (2012), 122–131.
101. Kondo, J., Endo, H., Okuyama, H., Ishikawa, O., Iishi, H., Tsujii, M., et al. Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A 108 (2011), 6235–6240.
102. Kuss, J.T., Muss, H.B., Hoen, H., Case, L.D., Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 42:3 (1997), 265–274.
103. van Landeghem, A.A., Poortman, J., Nabuurs, M., Thijssen, J.H., Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45:6 (1985), 2900–2906.
104. Lazarus, P., Blevins-Primeau, A.S., Zheng, Y., Sun., D., Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci 1155 (2009), 99–111.
105. Lee, A.V., Jackson, J.G., Gooch, J.L., Hilsenbeck, S.G., Coronado-Heinsohn, E., Osborne, C.K., et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:5 (1999), 787–796.
106. Leonard, R.C., Williams, S., Tulpule, A., Levine, A.M., Oliveros, S., Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 18:4 (2009), 218–224.
107. Lim, J.S., Chen, X.A., Singh, O., Yap, Y.S., Ng, R.C., Wong, N.S., et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol 71:5 (2011), 737–750.
108. Liotta, L., Petricoin, E., Molecular profiling of human cancer. Nat Rev Genet 1:1 (2000), 48–56.
109. Loeb, L.A., Loeb, K.R., Anderson, J.P., Multiple Mutations and Cancer. 2003.
110. Loessner, D., Stok, K.S., Lutolf, M.P., Hutmacher, D.W., Clements, J.A., Rizzi, S.C., Bioengineered 3D platform to explore cell–ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 31:32 (2010), 8494–8506.
111. Longo, D.L., Tumor heterogeneity and personalized medicine. N Engl J Med 366:10 (2012), 956–957.
112. Lu, P., Weaver, V.M., Werb, Z., The Extracellular Matrix: A Dynamic Niche in Cancer Progression. 2012.
113. Majety, M., Pradel, L.P., Gies, M., Ries, C.H., Fibroblasts influence survival and therapeutic response in a 3D co-culture model. PLoS One, 10, 2015.
114. Mao, Y., Keller, E.T., Garfield, D.H., Shen, K., Wang, J., Stroma cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32:0 (2013), 303–315.
115. Marchese, S., Silva, E., Disruption of 3D MCF-12A breast cell cultures by estrogens—an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis. PLoS One, 7(10), 2012, e45767.
116. Marchionni, L., Wilson, R.F., Marinopoulos, S.S., Wolff, A.C., Parmigiani, G., Bass, E.B., et al. Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep/Technol Assess (Full Rep)(160), 2007, 1–105.
117. Markovina, S., Callander, N.S., O′Connor, S.L., Kim, J., Werndli, J.E., Raschko, M., et al. Bortezomib-resistant NF-κB activity in multiple myeloma cells. Mol Cancer Res 6:8 (2008), 1356–1364.
118. Massarweh, S., Schiff, R., Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13:Suppl. 1 (2006), S15–S24.
119. Matsuo, K., Eno, M.L., Im, D.D., Rosenshein, N.B., Sood, A.K., Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol 116:1 (2010), 61–65.
120. Matsuoka, H., Tsubaki, M., Yamazoe, Y., Ogaki, M., Satou, T., Itoh, T., et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res 315:12 (2009), 2022–2032.
121. McAlpine, J.N., Eisenkop, S.M., Spirtos, N.M., Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol Oncol 110:3 (2008), 360–364.
122. McCallum, H.M., Lowther, G.W., Long-term culture of primary breast cancer in defined medium. Breast Cancer Res Treat 39:3 (1996), 247–259.
123. McDonnell, D.P., Norris, J.D., Connections and regulation of the human estrogen receptor. Science 296:5573 (2002), 1642–1644.
124. McNamara, D.A., Harmey, J., Wang, J.H., Kay, E., Walsh, T.N., Bouchier-Hayes, D.J., Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 27:8 (2001), 714–718.
125. Mehta, R.S., Bornstein, R., Yu, I.R., Parker, R.J., McLaren, C.E., Nguyen, K.P., et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res Treat 66:3 (2001), 225–237.
126. Mi, Z., Holmes, F.A., Hellerstedt, B., Pippen, J., Collea, R., Backner, A., et al. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 28:3b (2008), 1733–1740.
127. Mitra, A., Mishra, L., Li, S., Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol 31:6 (2013), 347–354.
128. Mobley, J.A., Brueggemeier, R.W., Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 25:1 (2004), 3–9.
129. Mor, G., Yue, W., Santen, R.J., Gutierrez, L., Eliza, M., Berstein, L.M., et al. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 67:5–6 (1998), 403–411.
130. Morales, D.E., McGowan, K.A., Grant, D.S., Maheshwari, S., Bhartiya, D., Cid, M.C., et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 91:3 (1995), 755–763.
131. Musgrove, E.A., Sutherland, R.L., Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:9 (2009), 631–643.
132. Mustata, R.C., Vasile, G., Fernandez-Vallone, V., Strollo, S., Lefort, A., Libert, F., et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep 5:2 (2013), 421–432.
133. Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:4 (2005), 721–747.
134. Novaro, V., Roskelley, C.D., Bissell, M.J., Collagen-IV and laminin-1 regulate estrogen receptor α expression and function in mouse mammary epithelial cells. J Cell Sci 116:Pt 14 (2003), 2975–2986.
135. Nyga, A., Cheema, U., Loizidou, M., 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 5 (2011), 239–248.
136. Obeid, E., Nanda, R., Fu, Y.X., Olopade, O.I., The role of tumor-associated macrophages in breast cancer progression. Int J Oncol 43 (2013), 5–12.
137. OECD, Proposal for a Template and Guidance on Developing and Assessing the Completeness of Adverse Outcome Pathways. 2012, OECD.
138. OECD, Users' handbook supplement to the guidance document for developing and assessing AOPs., 2013 Retrieved from https://aopkb.org/common/AOP_Handbook.pdf.
139. Ogino, S., Fuchs, C.S., Giovannucci, E., How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 12:6 (2012), 621–628.
140. O'Lone, R., Frith, M.C., Karlsson, E.K., Hansen, U., Genomic targets of nuclear estrogen receptors. Mol Endocrinol 18:8 (2004), 1859–1875.
141. Ong, S.M., Zhao, Z., Arooz, T., Zhao, D., Zhang, S., Du, T., et al. Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials 31:6 (2010), 1180–1190.
142. Orlando, L., Schiavone, P., Fedele, P., Calvani, N., Nacci, A., Rizzo, P., et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev 36:Suppl. 3 (2010), S67–S71.
143. Osborne, C.K., Schiff, R., Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62 (2011), 233–247.
144. Pak, C., Callander, N.S., Young, E.W., Titz, B., Kim, K., Saha, S., et al. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb) 7:6 (2015), 643–654.
145. Pampaloni, F., Reynaud, E.G., Stelzer, E.H.K., The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8:10 (2007), 839–845.
146. Pan, T., Fong, E.L., Martinez, M., Harrington, D.A., Lin, S.H., Farach-Carson, M.C., et al. Three-dimensional (3D) culture of bone-derived human 786-O renal cell carcinoma retains relevant clinical characteristics of bone metastases. Cancer Lett 365:1 (2015), 89–95.
147. Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladanyi, M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2(1), 2005.
148. Paoletti, C., Muniz, M.C., Thomas, D.G., Griffith, K.A., Kidwell, K.M., Tokudome, N., et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res 21:11 (2015), 2487–2498.
149. Pickl, M., Ries, C.H., Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28:3 (2008), 461–468.
150. Place, A.E., Jin Huh, S., Polyak, K., The microenvironment in breast cancer progression: biology and implications for treatment. (in review) Breast Cancer Res, 13(6), 2011, 227.
151. Platet, N., Cathiard, A.M., Gleizes, M., Garcia, M., Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:1 (2004), 55–67.
152. Provenzano, P.P., Eliceiri, K.W., Campbell, J.M., Inman, D.R., White, J.G., Keely, P.J., Collagen reorganization at the tumor–stromal interface facilitates local invasion. (Research article) BMC Med, 4(1), 2006, 38.
153. Provenzano, P.P., Inman, D.R., Eliceiri, K.W., Knittel, J.G., Yan, L., Rueden, C.T., et al. Collagen density promotes mammary tumor initiation and progression. (Research article) BMC Med, 6(1), 2008, 11.
154. Richard, S., Wells, A., Connor, J., Price, F., Use of ChemoFx(R) for identification of effective treatments in epithelial ovarian cancer. PLoS Curr, 7, 2015.
155. Roden, D.M., Pulley, J.M., Basford, M.A., Bernard, G.R., Clayton, E.W., Balser, J.R., et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 84:3 (2008), 362–369.
156. Roop, R.P., Ma, C.X., Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. Future Oncol 8:3 (2012), 273–292.
157. Ruppen, J., Wildhaber, F.D., Strub, C., Hall, S.R., Schmid, R.A., Geiser, T., et al. Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform. Lab Chip 15:14 (2015), 3076–3085.
158. Russo, J., Russo, I.H., The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102:1–5 (2006), 89–96.
159. Sachs, N., Clevers, H., Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev 24 (2014), 68–73.
160. Sackmann, E.K., Fulton, A.L., Beebe, D.J., The present and future role of microfluidics in biomedical research. Nature 507 (2014), 181–189.
161. Sadlonova, A., Novak, Z., Johnson, M.R., Bowe, D.B., Gault, S.R., Page, G.P., et al. Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res 7 (2005), R46–R59.
162. Saji, S., Kawakami, M., Hayashi, S., Yoshida, N., Hirose, M., Horiguchi, S., et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24:28 (2005), 4531–4539.
163. Salmon, S.E., Hamburger, A.W., Soehnlen, B., Durie, B.G., Alberts, D.S., Moon, T.E., Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:24 (1978), 1321–1327.
164. Samson, D.J., Seidenfeld, J., Ziegler, K., Aronson, N., Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22:17 (2004), 3618–3630.
165. Santen, R.J., Santner, S.J., Pauley, R.J., Tait, L., Kaseta, J., Demers, L.M., et al. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?. J Steroid Biochem Mol Biol 61:3–6 (1997), 267–271.
166. Santini, M.T., Rainaldi, G., Indovina, P.L., Multicellular tumour spheroids in radiation biology. Int J Radiat Biol 75:7 (1999), 787–799.
167. Sasai, Y., Eiraku, M., Suga, H., In vitro organogenesis in three dimensions: self-organising stem cells. Development 139:22 (2012), 4111–4121.
168. Sastre-Serra, J., Nadal-Serrano, M., Pons, D.G., Roca, P., Oliver, J., Mitochondrial dynamics is affected by 17beta-estradiol in the MCF-7 breast cancer cell line. Effects on fusion and fission related genes. Int J Biochem Cell Biol 44:11 (2012), 1901–1905.
169. Sastre-Serra, J., Nadal-Serrano, M., Pons, D.G., Valle, A., Oliver, J., Roca, P., The effects of 17β-estradiol on mitochondrial biogenesis and function in breast cancer cell lines are dependent on the ERα/ERβ ratio. Cell Physiol Biochem 29:1–2 (2015), 261–268.
170. Sastre-Serra, J., Valle, A., Company, M.M., Garau, I., Oliver, J., Roca, P., Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med 48:4 (2010), 506–512.
171. Sato, T., Stange, D.E., Ferrante, M., Vries, R.G., Van Es, J.H., Van den Brink, S., et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141:5 (2011), 1762–1772.
172. Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N., Stange, D.E., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459:7244 (2009), 262–265.
173. Sawyers, C., Targeted cancer therapy. Nature 432:7015 (2004), 294–297.
174. Schrag, D., Garewal, H.S., Burstein, H.J., Samson, D.J., Von Hoff, D.D., Somerfield, M.R., American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22:17 (2004), 3631–3638.
175. Sengupta, K., Banerjee, S., Saxena, N., Banerjee, S.K., Estradiol-induced vascular endothelial growth factor—a expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway. Int J Oncol 22:3 (2003), 609–614.
176. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3(75), 2011, 75ra26.
177. Sevin, B.U., Peng, Z.L., Perras, J.P., Ganjei, P., Penalver, M., Averette, H.E., Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31:1 (1988), 191–204.
178. Shamir, E.R., Ewald, A.J., Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol 15 (2014), 647–664.
179. Shield, K., Ackland, M.L., Ahmed, N., Rice, G.E., Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 113:1 (2009), 143–148.
180. Shou, J., Massarweh, S., Osborne, C.K., Wakeling, A.E., Ali, S., Weiss, H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:12 (2004), 926–935.
181. Sikora, K., Advani, S., Koroltchouk, V., Magrath, I., Levy, L., Pinedo, H., et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol 10:4 (1999), 385–390.
182. Simoncini, T., Mannella, P., Fornari, L., Caruso, A., Varone, G., Genazzani, A.R., Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69:8–9 (2004), 537–542.
183. Simpson, E.R., Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86:3–5 (2003), 225–230.
184. Singer, C.F., Klinglmuller, F., Stratmann, R., Staudigl, C., Fink-Retter, A., Gschwantler, D., et al. Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay. PLoS One, 8(6), 2013, e66573.
185. Soon, P.S., Kim, E., Pon, C.K., Gill, A.J., Moore, K., Spillane, A.J., et al. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr Relat Cancer 20:1 (2013), 1–12.
186. Sounni, N.E., Noel, A., Targeting the tumor microenvironment for cancer therapy. Clin Chem 59:1 (2013), 85–93.
187. Sung, K.E., Su, X., Berthier, E., Pehlke, C., Friedl, A., Beebe, D.J., Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One, 8(10), 2013, e76373.
188. Takebayashi, K., Mekata, E., Sonoda, H., Shimizu, T., Endo, Y., Tani, T., Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer. Cancer Chemother Pharmacol 72:1 (2013), 217–222.
189. Tan, J., Buache, E., Chenard, M.P., Dali-Youcef, N., Rio, M.C., Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int J Dev Biol 55:7–9 (2011), 851–859.
190. Tan, M.E., Li, J., Xu, H.E., Melcher, K., Yong, E.-l., Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 36:1 (2014), 3–23.
191. Tan, M.H., Li, J., Xu, H.E., Melcher, K., Yong, E.L., Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 36:1 (2015), 3–23.
192. Thompson, E.W., Reich, R., Shima, T.B., Albini, A., Graf, J., Martin, G.R., et al. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res 48:23 (1988), 6764–6768.
193. Tibbitt, M. W., Department of Chemical and Biological Engineering, U. o. C., Boulder, Colorado, Anseth, K. S., Department of Chemical and Biological Engineering, U. o. C., Boulder, Colorado, Howard Hughes Medical Institute, U. o. C., Boulder, Colorado, 303-492-7471, t., et al. (2015). Hydrogels as extracellular matrix mimics for 3D cell culture. Biotechnology and Bioengineering, 103(4), 655–663.
194. Tomalik-Scharte, D., Lazar, A., Fuhr, U., Kirchheiner, J., The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:1 (2007), 4–15.
195. Tsimberidou, A.-M., Iskander, N.G., Hong, D.S., Wheler, J.J., Falchook, G.S., Fu, S., et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. 2012.
196. Tuxhorn, J.A., Ayala, G.E., Smith, M.J., Smith, V.C., Dang, T.D., Rowley, D.R., Reactive stroma in human prostate cancer. Clin Cancer Res, 8, 2002.
197. Ugurel, S., Schadendorf, D., Pfohler, C., Neuber, K., Thoelke, A., Ulrich, J., et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 12:18 (2006), 5454–5463.
198. Veer, L.J.V.T., Bernards, R., Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452:7187 (2008), 564–570.
199. Vinken, M., The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312 (2013), 158–165.
200. Wang, T.T., Phang, J.M., Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55:12 (1995), 2487–2489.
201. Wang, T.N., Albo, D., Tuszynski, G.P., Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 132 (2002), 220–225 (United States).
202. Weaver, V.M., Petersen, O.W., Wang, F., Larabell, C.A., Briand, P., Damsky, C., et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:1 (1997), 231–245.
203. Webb, P., Lopez, G.N., Uht, R.M., Kushner, P.J., Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:4 (1995), 443–456.
204. Weiswald, L.B., Bellet, D., Dangles-Marie, V., Spherical cancer models in tumor biology. Neoplasia 17:1 (2015), 1–15.
205. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161:4 (2015), 933–945.
206. Williams, J.A., Phillips, D.H., Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 60:17 (2000), 4667–4677.
207. Wilmes, A., Limonciel, A., Aschauer, L., Moenks, K., Bielow, C., Leonard, M.O., et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics 79 (2013), 180–194.
208. Wolf, K., Alexander, S., Schacht, V., Coussens, L.M., von Andrian, U.H., van Rheenen, J., et al. Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol 20:8 (2009), 931–941.
209. Wu, B., Zhu, J.S., Zhang, Y., Shen, W.M., Zhang, Q., Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution's experience. World J Gastroenterol 14:19 (2008), 3064–3068.
210. Xu, X., Farach-Carson, M.C., Jia, X., Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv 32:7 (2014), 1256–1268.
211. Xu, Z., Gao, Y., Hao, Y., Li, E., Wang, Y., Zhang, J., et al. Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer. Biomaterials 34:16 (2013), 4109–4117.
212. Xu, Y., Sun., Y., Yao, L., Shi, L., Wu, Y., Ouyang, T., et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:8 (2008), 1423–1429.
213. Yager, J.D., Davidson, N.E., Estrogen carcinogenesis in breast cancer. N Engl J Med 354:3 (2006), 270–282.
214. Yamada, K.M., Cukierman, E., Modeling tissue morphogenesis and cancer in 3D. Cell 130:4 (2007), 601–610.
215. Yamaguchi, Y., Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer 14:2 (2007), 175–181.
216. Yamamoto, M., Hosoda, M., Nakano, K., Jia, S., Hatanaka, K.C., Takakuwa, E., et al. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 105:1 (2014), 81–88.
217. Yang, J., Liu, A., Dougherty, C., Chen, X., Guzman, R., Nandi, S., Estrogen and progesterone receptors can be maintained in normal human breast epithelial cells in primary culture and after transplantation into nude mice. Oncol Rep 7:1 (2000), 17–21.
218. Young, E.W.K., Beebe, D.J., Fundamentals of microfluidic cell culture in controlled microenvironments. Chem Soc Rev, 39(3), 2010.
219. Young, E.W.K., Pak, C., Kahl, B.S., Yang, D.T., Callander, N.S., Miyamoto, S., et al. Microscale functional cytomics for studying hematologic cancers. Blood, 119(10), 2012.
220. Zervantonakis, I.K., Hughes-Alford, S.K., Charest, J.L., Condeelis, J.S., Gertler, F.B., Kamm, R.D., Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc Natl Acad Sci U S A 109:34 (2012), 13515–13520.
221. Zhang, X.H., Giuliano, M., Trivedi, M.V., Schiff, R., Osborne, C.K., Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res 19:23 (2013), 6389–6397.
222. Zhang, G.J., Kimijima, I., Onda, M., Kanno, M., Sato, H., Watanabe, T., et al. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res 5:10 (1999), 2971–2977.
223. Zheng, S., Huang, J., Zhou, K., Zhang, C., Xiang, Q., Tan, Z., et al. 17β-estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein Ezrin. PLoS One, 6, 2011.
224. Zivadinovic, D., Gametchu, B., Watson, C.S., Membrane estrogen receptor-α levels in MCF-7 breast cancer cells predict cAMP and proliferation responses. (Research article) Breast Cancer Res, 7(1), 2004.